FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma [PDF]
Therapeutic Advances in Medical Oncology, 2021 Background: Most patients with advanced pancreatic adenocarcinoma (PA) treated with FOLFIRINOX experience adverse events requiring dose reduction. We aimed to assess the association between relative dose intensity (RDI) and disease control in a European ...
Antonin Vary +11 more
doaj +8 more sources
Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas [PDF]
Cancer MedicineBackground Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent.
Stephen Poitureau +12 more
doaj +3 more sources
Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma [PDF]
SAGE Open Medicine, 2018 Objectives: To evaluate the impact of relative dose intensity for gemcitabine–cisplatin chemotherapy in patients with metastatic urothelial carcinoma.
Naoki Kohei +6 more
doaj +5 more sources
Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials [PDF]
Contemporary Clinical Trials Communications, 2019 The recommended phase 2 doses of molecularly targeted agents, determined by using an ordinal dose-finding method that only uses toxicity data at first cycle, may not be optimal.
Akihiro Hirakawa +2 more
doaj +4 more sources
Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study [PDF]
BMC Cancer, 2021 Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy
Jolanta Żok +5 more
doaj +2 more sources
Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity [PDF]
PharmaceuticalsObjectives: The multidisciplinary city-hospital Oncoral follow-up of cancer outpatients has been set up to ensure the safety of oral anticancer drugs (OADs).
Virginie Larbre +13 more
doaj +2 more sources
Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study [PDF]
Journal of Pharmaceutical Health Care and Sciences, 2018 Background S-1 (a combination of tegafur, gimeracil, and oteracil) is used to treat various cancers. Bone marrow suppression is a dose-limiting toxicity of S-1.
Toshinori Hirai +3 more
doaj +2 more sources
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study [PDF]
Therapeutic Advances in Medical OncologyBackground: Platinum-based chemotherapy is the first-line treatment choice for advanced thymic epithelial tumors (TETs), with the expected objective response rate (ORR) ≈of 50% in thymoma and ≈20% in thymic carcinoma. Objective: To evaluate the impact of
Erica Pietroluongo +13 more
doaj +2 more sources
CYP2J2∗7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients [PDF]
Frontiers in Pharmacology, 2019 Chemotherapy-induced hematologic toxicity is the primary reasons of dose reductions and/or delays, low relative dose intensity (RDI), and predicts anticancer response.
Jemal Hussien Ahmed +13 more
doaj +2 more sources
Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine [PDF]
Cancer Medicine, 2019 We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high‐risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI)
Kamel Laribi +8 more
doaj +2 more sources